Download this application note to learn how new powder surfactants from Gattefossé can bring the bioavailability-enhancing benefits of lipid excipients to directly compressible tablets and hard capsules.
An oral administration route is the easiest and preferred route for prescribers and patients. When looking at the recent and upcoming pharmaceutical developments for oral dosage forms, solid forms – those include tablets and hard capsules – are the main drugs brought to the market. Another aspect to consider is the rising prevalence of APIs requiring solubility and/or permeability enhancement.
Lipid excipients improve API bioavailability by increasing solubility and permeability. Commonly liquid or waxy, they were primarily formulated in liquid dosage forms. However, recent developments at Gattefossé opened the path for new powder surfactants, directly processable in tablets or hard capsules.
LabraSolid and GSolid products are the fruit of Gattefossé own research and development. Preliminary studies demonstrated their good processability across different manufacturing processes, and their bioavailability enhancement properties.
In this application note you will find out:
- How lipid-based excipients can improve API solubility and permeability to enhance bioavailability
- How LabraSolid and GSolid provide powder surfactant alternatives to traditionally liquid or waxy lipid excipients in oral solid dosage forms
- Explore real case studies of LabraSolid and GSolid and their application in oral solid dosage forms
Download the application note to explore the properties of LabraSolid and GSolid, alongside real case studies demonstrating their application in oral solid dosage forms.
Download Now
No comments yet